Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered
subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Introduction: Obesity is a global epidemic affecting 2.5 billion people and is recognized as
the fourth leading cause of global mortality. Obesity is characterized by excessive …

Background: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

More than half the world population is expected to be overweight or obese by the year 2035
[1]. Obesity and atherosclerotic cardiovascular disease have always been a fatal …

Overweight or obesity has been independently associated with increased cardiovascular
risk, yet interventional trials of lifestyle or pharmacologic management strategies for …

Previous studies have shown benefits of the Glucagon-like peptide (GLP-1) receptor agonist
Semaglutide (Wegovy, Ozempic) to reduce cardiovascular events in overweight/obese …

• In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or
Obesity trial, the SELECT Investigators tested the hypothesis that the addition of …

Conclusive evidence have shown the cardiovascular benefits of semaglutide (1 mg weekly)
in people with type 2 diabetes. 1 Recent data have also confirmed the efficacy of high dose …

The independent association between overweight, obesity, and an increased risk of
cardiovascular events emphasizes the urgent need for effective interventions to mitigate this …